Exposure-Efficacy Meta-model of Nintedanib in Adult Patients with Chronic Fibrosing Interstitial Lung Diseases

CPT Pharmacometrics Syst Pharmacol. 2025 Nov 21. Online ahead of print.
Hartman S, Janssen J, Ribbing J, Stowasser S, Korell J.
JournalMethodologyMIDDPharmacometricsProgram strategies and efficienciesRegulatory interactionsRespiratorySpecial/specific populations

Read more about this publication

Pharmetheus Affiliates

Portrait-of-Julie-Janssen_Pharmetheus-1
Senior Director, MIDD Consultant

Julie Janssen

See bio
Portrait-of-Jakob-Ribbing_Pharmetheus-1
Principal Director, MIDD Consultant & Senior Expert

Jakob Ribbing

See bio